In re of THOGERSEN=1

stable triple alpha helical coiled coil complex with two other

TTSEs, [with the proviso that] where (a) the heterologous moiety

is different from any of the fusion proteins CIIH6FXTN123,

H6FXTN123, H6FXTN12M H6FCTN23, the sequences of which are shown in

SEQ ID NOs:24-27[.]; and/or (b) at least one heterologous moiety

being one in which does not exclusively facilitate expression

and/or purification of the monomen polypeptide construct.

2 (amended). [A] The monomer polypeptide construct [comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable triple alpha helical coiled toil complex with two other TTSEs, said at least one geterologous moiety being one which does not exclusively facilitate expression and/or purification of the monomer polypeptide construct] of claim 1 where (a) applies. --

Claim 3, line 1, replace "A" with --The--; and line 1, replace "any of the preceding claims" with --claim 1--.

Claim A, line 1, replace "A" with --The--; and line 1, replace "any of the preceding claims" with --claim 1--.

Claim 5, line 1, replace "A" with --The--.

Claim 6, line 1, replace "A" with --The--; and
line 1, delete "or 5".

Claim 7, line 1, replace "A" with --The--; and
line 1, replace "any of claims 1-3" with

--claim 1--.

Claim 8, line 1, replace "A" with --The--; and line 1, replace "any of the preceding claims" with --claim 1--.

Claim 9, line 1, replace "A" with --The--.

Claim 10, line 1, replace "A" with --The--; and

line 2, delete "such as at least 81%m at least

87%, or at least 92%".

Claim 11, line 1, replace "A" with --The--; and line 1, replace "any of claims 8-10" with

--claim 8--.

Į,fi

Claim 12, line 1, replace "A" with --The--; and line 1, replace "any of the preceding claims" with --claim 1--.

Claim 13, line 1, replace "A" with --The--.

Claim 14, line 1, replace "A" with --The--; and line 1, replace "any of the preceding claims"

with --claim 1--.

Claim 15, line 1, replace "A" with --The--; and line 1, replace "any of the preceding claims" with --claim 1--.

Claim 16, line 1, replace "A" with --The--; and line 1, replace "any of the preceding claims" with --claim 1--.

Claim 17, line 1, replace "A" with --The--; and

line 1, replace "any of the preceding claims" with --claim 1--.

Claim 18, line 1, replace "A" with --The--; and line 1, replace "any of the preceding claims" with --claim 1--.

-- 19 (amended). An oligomer [which is comprised of] comprising at least two monomer polypeptide constructs according to [any of claims 1-18 and which comprises at least three TTSE's or a multiplum of three TTSE's, or which is comprised of three monomer polypeptide constructs according to any of claims 1-3 or 7-18] claim 1. --

Claim 21, line 1, delete "or 20".

Claim 24, line 1, replace "any of claims 19-23" with 1 -- claim 19--.

Claim 25, line 1, replace "any of claims 1-18" with --claim 1--.

Claim 26, line 1, delete "according to claim 19"; line 2, replace "any of claims 1-18" with --claim 1--; and

lines 3 and 4, replace "any of claims 1-3 or 7-18" with --claim 1--.

Claim 27, line 1, delete "according to claim 19"; and line 2, replace "any of claims 1-18" with

--claim 1--.

A3

(3

ľħ

Claim 28, line 3, replace "any of claims 1-18" with --claim 1--;

In re of THOGERSEN=1

lines 5 and 6, replace "any of claims 1-18" with --claim 1--; and

lines 9 and 10, replace "any of claims 1-3 or 7-18" with --claim 1--.

Claim 30, line 1, delete "or 29".

Claim 31, line 1, replace "any of claims 1-18" with --claim 1--; and

lines 2 and 3, replace "any of claims 1-18" with --claim 1--.

Delete claim 34 in its entirety.

Claim 35, line 1, replace "use" with --method--; and line 1, replace "34" with --65--; and line 1, replace "moity" with --moiety--.

-- 36 (amended). [The use of a monomer polypeptide construct according to any of claims 1-18 or to a an oligomer according to any of claims 9-24 as a] A component of a chimaeric product having low antigenicity in humans relative to formulations comprising one or more components of non-human origin, and comprising at least one monomer polypeptide construct according to claim 1.

37 (amended) [The use] <u>The a method</u> of [a monomer polypeptide construct according to any of claims 1-18 or to a an oligomer according to any of claims 19-24 as a vehicle for] assembling antibody fragments into oligometric or multivalent entities for generating chimeric artificial antibodies having preselected pharmacokinetic and/or pharmadynamic properties <u>the</u>

A4

improvement which comprises use of at least one monomer polypeptide construct according to claim 1 as a vehicle.

A4 concld

#ñ

١. ا

38 (amended). The [use] method of claim 48 comprising [a monomer polypeptide construct according to any of claims 1-18 or to a an oligomer according to any of claims 19-24 for] delivering an imaging or toxin-conjugated antibody to a tumor.

39 (amended). [The use of a monomer polypeptide construct according to any of claims 1-18 or to a oligomer according to any of claims 19-24 as a vehicle delivering an] In a method of delivering a substance to a target cell or tissue, the improvement which comprises use of a conjugate of said substance and at least one monomeric polypeptide construct according to claim 1. --

Delete claims 40 46 in their entirety.

-- 47 (amended). [The use according to any of claims 34 to 46 wherein the] A composition comprising at least one monomer polypeptide construct according to claim 1 [any of claims 1-18 or the oligomer according to any of claims 19-21 is comprised] in a liposome.

48 (amended). A method for treating or preventing a disease comprising administering to [the] a subject in need thereof a therapeutically or prophylactically effective amount of a [an effective amount of a pharmaceutical composition as defined in any of claims 44 and 45] pharmaceutically acceptable composition comprising

(a) a pharmaceutical comprising at least one monomer

In re of THOGERSEN=1

polypeptide construct according to claim 1, or

(b) a gene therapy reptor comprising DNA encoding a pharmaceutical of (a) above.

Delete claims 49 and 50 in their entirety.

Claim 51 lines 1 and 2, replace "A method of human gene therapy comprising use of a monomer polypeptide construct according to any of claims 1-18 or to an oligomer according to any of claims 19-24" with --The method of claim 65--.

Claim 52, line 1, replace "A" with --The--;

line 1, replace "any of claims 48 to 51"

with

--claim 48--;

lines 2 and 3, replace "monomer polypeptide"

[] construct according to any of claims 1-18 or the oligomer

[] according to any of claims 19-24" with --composition--; and

line 6, delete "such as a tumour".

Delete claim 53 in its entirety.

-- 54 (amended). A method for diagnosis of a disease comprising a [construct comprising the monomer polypeptide construct according to any of claims 1-18 or the oligomer according to any of claims 19-24 together with a diagnosing component coupled thereon contacting a sample with a diagnostic agent according to claim 66, and correlating the degree of interaction between the agent and the sample, with the status of the disease. --

Please and the following claims:

A7 t

^{-- 55.} The monomer polypeptide construct of claim 1

where (b) \backslash applies.

- 6. The monomer polypeptide construct of claim 2 where (b) applies.
- 57. The monomer polypeptide construct of claim 1 which comprises a plurality of TTSEs.
- 58. The monomer polypeptide construct of claim 1 which comprises at least three TTSEs.
- 59. The monomer polypeptide construct of claim 1 which has exactly an integer (≥1) multiple of three TTSEs.
- 60. The oligomer of claim 24, comprising at least three monomer polypeptide constructs.
- 61. An oligomer comprising at least two monomer polypeptide constructs according to claim 59.
- 62. The method of claim 48 in which the pharmaceutical is a monomer polypeptide construct.
 - 63. The method of claim 48 in which the pharmaceutical is an oligomer comprising at least two mononomer polypeptide constructs.
 - 64. The method of claim 48 in which (a) is administered.
 - 65. The method of claim 48 in which (b) is administered.
 - 66. A diagnostic agent comprising at least one monomer polypeptide construct according to claim 1, and a detectable label or an insoluble support.

8

67. In a method of displaying a protein library the

MX

il the service and service ser

13